123 results about "Colony formation" patented technology

The invention relates to a self-adaptive scaling formation cooperation method for unmanned swarms, the unmanned swarms can realize self-adaptive formation scaling according to a complex environment, the flight safety of the unmanned swarms is ensured, and the method can be widely applied to multiple fields of public safety monitoring, environmental protection monitoring, agricultural management, traffic dispersion and the like. Through cooperative obstacle avoidance and formation, tasks can be efficiently and accurately completed in a complex environment, real-time data support is provided, and powerful guarantee is provided for development of various fields. Along with continuous maturation of the technology, the application prospect of unmanned bee colony formation and obstacle avoidance collaboration is wider.

Aspects of the present disclosure relate to a method of colony enumeration. The method includes identifying colony forming units of microorganisms in a combined image using a pretrained deep learning model on a colony enumeration device. The method can include providing a plurality of identification characteristics of the colony forming units to an interaction component such that the interaction component can project at least some of the plurality of identification characteristics onto the combined image.

The invention relates to the fields of epigenetic regulation and tumor treatment, and aims to evaluate that the cell distribution of the mutant is consistent with that of H3 by constructing Bas-2B (H3K9R) and Bas-2B (H3K18R) stably transfected cell strains and analyzing the cell positioning condition of the H3K9R / H3K18R mutant through an immunofluorescence technique. According to the present invention, a Western blotting technology is adopted to detect the H3K9 / H3K18 lactic acid modification level of Bas-2B (H3K9R) and Bas-2B (H3K18R) cells compared to control cells so as to verify the influence of the H3K9R / H3K18R mutant on the H3K9 / H3K18 lactic acid modification; after Bas-2B (H3K9R), Bas-2B (H3K18R) cells and control cells of the Bas-2B (H3K9R) and the Bas-2B (H3K18R) cells are subjected to nickel compound exposure treatment, the influence of the H3K9R / H3K18R mutant on the nickel compound induced lung cancer is evaluated through a soft agar cloning formation experiment. An AGS cell line stably transfecting H2BK16R is constructed, and the cell localization condition of the H2BK16R mutant is analyzed through an immunofluorescence technology. According to the present invention, a Westernbloting technology is adopted to detect the lactic acid modification level of AGS (H2BK16R) cells so as to verify the influence of the H2BK16R mutant on the H2BK16 lactic acid modification; the influence of the H2BK16R on the malignant proliferation ability of the gastric cancer is researched through a soft agar clone formation experiment.

A bacterial colony forming unit (CFU) detection system is disclosed that utilizes a thin film transistor (TFT)-based image sensor array that saves about 12 hours compared to methods approved by Environmental Protection Agency (EPA). Lensless imaging modes are constructed using TFT image sensors having a sample field of view of about 10 cm2. And automatically collecting delay images of bacterial colonies cultured on the chromogenic agar plate every 5 minutes. Two deep neural networks are used to detect and count colonies in growth and identify their species. When 265 escherichia coli and other coliforms (namely citrobacter and klebsiella pneumoniae) colonies are used for blind detection, the average CFU detection rate of the system reaches 97.3% when the system is cultured for 9 hours, and the average recovery rate of the system reaches 91.6% when the system is cultured for about 12 hours. The TFT-based sensor can be applied to various microbiological detection methods. The imaging field of view of the platform can be economically and efficiently increased to more than 100cm < 2 >.

Provided is an antibody fusion protein, which simultaneously targets CD24, IL4R and an integrin receptor. An in-vitro assay shows that the antibody fusion protein significantly inhibits the proliferation, migration, invasion, colony formation and adhesion of renal cancer cells, also has a comprehensive and significant anti-tumor effect on gastric cancer, colon cancer and breast cancer, and has the effect of inhibiting angiogenesis. The results of a mouse tumor model of subcutaneous transplantation of MC38-hPDL1C57BL6 / J show that the antibody fusion protein combined with the PDL1 antagonist atezolizumab can significantly inhibit tumor growth. The antibody fusion protein can be used as a potential candidate drug for treating metastatic renal cell carcinoma, PDL1-overexpressing cancer, ophthalmic diseases and inflammation or autoimmune diseases.

A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 1×1010 CFU / g, and a viability loss of less than 1 log unit / g after one month at a temperature of 40° C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.

The invention relates to a Kluyveromyces marxianus YZC-01 solid preparation for improving the delicate flavor of mutton, which contains living cells of a Kluyveromyces marxianus YZC-01 strain, and the colony forming unit (CFU) of the Kluyveromyces marxianus YZC-01 solid preparation is 1.0 * 10 < 8 > / g to 10.0 * 10 < 8 > / g. The invention further relates to application of the kluyveromyces marxianus YZC-01 solid preparation in improvement of the delicate flavor of mutton, and results show that by adding 0.01 wt%-1.0 wt% of the kluyveromyces marxianus solid preparation into sheep feed and / or drinking water, the growth rate of sheep can be increased by 3.0%-9.8%, the flavor nucleotides in the mutton can be increased by 1.29%-2.81%, and the flavor of the mutton can be increased by 1.29%-2.81%. The Kluyveromyces marxianus YZC-01 solid preparation disclosed by the invention has the advantages that the content of flavor amino acid in mutton is increased by 7.6%-28.0%, and the Kluyveromyces marxianus YZC-01 solid preparation has an important application prospect.

This invention provides a 2-sulfonylpyrimidine-4-amide compound and its uses, belonging to the field of antitumor drug technology. The compound of this invention exhibits excellent antitumor activity targeting the colchicine site of tubulin, demonstrating antiproliferative activity against tumor cells such as HeLa, HepG2, H1299, and MCF-7 at the micromolar level, and significantly inhibiting colony formation in a dose-dependent manner. Furthermore, the compound inhibits tubulin polymerization and disrupts the microtubule network of H1299 cells in vitro, inducing cell cycle arrest in the G2 / M phase and apoptosis. More importantly, the compound can inhibit angiogenesis in HUVECs in vitro. The compound of this invention has great potential in the preparation of microtubule destabilizing agents targeting the colchicine site.

The application relates to the field of biological medicine, and particularly relates to application of a TMEM119 gene or protein in development of an anti-gastric cancer drug, and particularly to application of a TMEM119 inhibitor in preparation of an anti-gastric cancer drug, wherein the inhibitor can be a small-molecule nucleotide for targeted knockdown of the TMEM119 gene or protein, the small-molecule nucleotide is shRNA or siRNA, the shRNA is a double-stranded oligonucleotide composed of complementary base sequences shown in SEQ ID NO. 1-2 or SEQ ID NO. 3-4; and the siRNA has a guide strand with a base sequence shown in SEQ ID NO. 7 or SEQ ID NO. 8. Experiments prove that when the expression of the TMEM119 gene of human gastric cancer cells is knocked down, the viability and the colony formation ability of the human gastric cancer cells are significantly reduced, thereby inhibiting the proliferation and survival of the gastric cancer cells, and further achieving the effect of restraining the occurrence, development, recurrence or metastasis of the gastric cancer.

The present invention provides the use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia, and relates to the field of leukemia therapeutics. The use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia according to the present invention addresses the problems of high incidence, poor prognosis and lack of effective drugs in STAG2 mutation acute myeloid leukemia. Fangchinoline can inhibit the proliferation and colony formation of AML cell lines SKM-1, Kasumi-6, THP-1 and U-937, induce apoptosis, cell cycle arrest and cell differentiation in these cells, and thus exert an anti-STAG2 mutation acute myeloid leukemia effect.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

The invention relates to application of an IP6 synthesis related kinase inhibitor in tumor radiotherapy sensitization. According to the application, CRISPR / Cas9 is used in vitro for screening important kinases in cells, it is found that the important kinases IPPK and ITPK1 participating in IP6 synthesis are related to radiotherapy sensitivity, and the research value of IPPK and ITPK1 serving as radiotherapy sensitization targets is further verified through cell colony formation experiments, mouse tumor-bearing induced radiotherapy tolerant cells and patient transcriptome data. In the aspect of mechanism and effect, it is found that targeted inhibition of IPPK and ITPK1 can promote lipid peroxidation induced by Fenton reaction by improving the level of free ferrous ions, so that ferroptosis is easier to occur, and sensitization can be achieved on radiotherapy which also causes lipid peroxidation. The invention provides a potential strategy for comprehensive treatment of malignant tumors, and has important practical significance for formulation of an accurate treatment scheme of malignant tumors clinically.

Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic mouse model of AML, which we evolved to develop resistance to a front-line chemotherapy regimen. The inventors identified SRRM1 as a critical vulnerability of chemoresistant leukemic cells and identified that PAK1 and CLK kinases are regulators of SRRM1 in chemoresistant AML cells. Human and murine chemoresistant cells were found to be markedly more sensitive to inhibitors of PAKs (FRAX597) and CLKs (TG003 and ML 167) compared to their naive counterparts, an effect which was even further enhanced by treatment with cytarabine and daunorubicin. Simultaneous suppression of Clk1 and Pak1 or Clk-4 and Pak1 using validated shRNAs and combinations of FRAX597 and TG003, or FRAX597 and ML 167 synergized to reduce the growth and the colony-forming capacity of chemoresistant AML cells and sensitized them to chemotherapy. The combined treatment improved overall mouse survival and reduced disease burden in the chemoresistant AML mouse models. Moreover, AML patient cells that were primarily refractory or from a post chemotherapy relapse (n=21 ) exhibited a higher ex vivo sensitivity to the FRAX597 + TG003 combination in comparison with chemosensitive patients at diagnosis (n=28). Finally, combined PAK1 and CLK inhibition more effectively reduced disease progression in animals transplanted with the relapse sample than in those engrafted with the sample taken at diagnosis. Thus, the present invention relates to combination of PAK1 inhibitors and CLK inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia.

The invention discloses a synthetic microbial flora for improving pork quality and application thereof. The synthetic microbial flora comprises two kinds of probiotics, namely lactobacillus plantarum WY2401 with the preservation number of CCTCC (China Center For Type Culture Collection) NO. The invention relates to ackermann muciniophilic bacteria. The synthetic microbial flora is prepared by compounding lactobacillus plantarum and ackermann mucophile according to a colony formation unit number ratio of 1: 1, concentrating and freeze-drying. Experimental results show that the synthetic microbial flora is added into the basic feed of the fattening pigs, so that the carcass traits are improved, the intramuscular fat content is increased, the conversion of muscle fiber types and the development of muscle fibers are promoted, and the meat quality is improved.

This useful solution, in the field of biotechnology and regenerative medicine, relates to a process for enhancing the efficiency of induced pluripotent stem cell (iPSC) colony formation from human peripheral blood mononuclear cells (PBMCs). The solution aims to overcome the low reprogramming efficiency, unstable colony formation, and limited iPSC cloning rates commonly encountered in PBMC iPSC generation processes. The technical essence of the solution lies in the synchronized optimization of the reprogramming process, including pre-activating PBMCs with an appropriate cytokine combination at predetermined times before reprogramming, using a non-integrated Sendai virus system under optimized transformation conditions, switching culture media at defined intervals to promote cell state transitions, and applying a selection, enrichment, and stabilization process for iPSC cloning in the initial passages after colony formation.The process also incorporates cell line quality control steps through assessment of residual Sendai virus RNA removal and mycoplasma contamination testing during line maintenance. Experimental results show that the proposed process increases the number of iPSC colonies formed, improves the rate of establishing stable iPSC lines, and enhances cell homogeneity and pluripotency maintenance. The solution can be applied in basic research, pathogenesis modeling, drug screening, regenerative medicine, and studies using induced pluripotent stem cells derived from human peripheral blood cells.

The application provides application of glutaroyl-CoA dehydrogenase in inducing ferroptosis of liver cancer cells, and belongs to the technical field of biotechnology.The application provides application of glutaroyl-CoA dehydrogenase (GCDH) in preparing products for evaluating risk of liver cancer and evaluating prognosis risk of liver cancer, and the tumor stage and T grade can be estimated by detecting the expression amount of GCDH, and the survival effect of liver cancer patients is evaluated.The application provides application of the overexpression reagent of GCDH in preparing products for inhibiting proliferation of liver cancer cells and inducing ferroptosis of liver cancer cells, and the ferroptosis of liver cancer cells is promoted by overexpressing GCDH in cells, and the colony formation ability of liver cancer cells is reduced.Further, the application provides application of the overexpression reagent of GCDH combined with a CA9 inhibitor in preparing products for inhibiting proliferation of liver cancer cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present invention discloses a semicarbazide derivative and its preparation method and application, which belongs to the technical field of anti-lung cancer targeted drugs. The semicarbazide derivative of the present invention can inhibit the growth of H1299 cells in a dose-dependent manner, but has little toxicity to normal lung epithelial cells BEAS-2B. The semicarbazide derivative of the present invention can significantly inhibit the cloning of non-small cell lung cancer cells A549 and H1299, so it has a significant inhibitory effect on the proliferation of non-small cell lung cancer. The semicarbazide derivative provided by the present invention can inhibit the protein expression of GPX4 in non-small cell lung cancer A549 cells, and by inhibiting the protein expression of GPX4, promote the ferroptosis of non-small cell lung cancer cells, thereby playing a role in suppressing tumors.

The invention discloses a method for predicting the air disinfectant dosage of aerosol. The method comprises the following steps: S1, sending biological aerosol into a disinfection chamber; s2, disinfecting the interior of the disinfection chamber; s3, in the disinfection process, collecting the naturally settled biological aerosol; s4, culturing the collected biological aerosol, counting colony formation units, and calculating the concentration of the biological aerosol to obtain the disinfection efficiency; s5, the conditions of the disinfection process and the disinfection efficiency are substituted into a disinfection mechanical formula for fitting to obtain all parameter values, and finally a disinfection dynamic formula under certain disinfectant concentration and disinfection action time is obtained and used for predicting the dosage of the used disinfectant when certain air disinfection efficiency is achieved. The method can standardize the use of an air disinfection mode and discuss the optimal use amount of a disinfectant, and can safely and efficiently remove pathogenic microorganisms in air.

This invention provides a human embryonic stem cell expansion culture medium, comprising DMEM / F12 medium, ITS-A, HEPES, magnesium ascorbate phosphate, non-essential amino acids, bFGF, FGF2-G3, GlutaMAX, LY-333531, gentamicin sulfate, Y27632, and CHIR99021. Y-27632 inhibits pluripotent stem cell apoptosis, improves adhesion efficiency, maintains pluripotency and colony formation ability; CHIR99021 enhances the self-renewal of pluripotent stem cells and inhibits their differentiation; LY-333531 inhibits spontaneous differentiation of pluripotent stem cells; and gentamicin sulfate reduces the risk of contamination during culture. The culture medium provided by this invention is serum-free, free of allogeneic substances, has a simple composition, and offers excellent expansion speed, effectively maintaining long-term stable passage of human embryonic stem cells, providing stable technical support for scientific research.

The invention relates to the technical field of biological medicine, in particular to a polypeptide inhibitor of a targeted MZF1 gene and application of the polypeptide inhibitor in colon cancer treatment, and a polypeptide compound named as 10PANX ACETATE is the first MZF1 gene efficient targeted inhibitor which is clearly recognized and has high uniqueness and innovativeness. In the field of biological medicines, the compound fills the blank of medicines for treating diseases caused by abnormal expression of MZF1. Through rigorous in-vitro and in-vivo animal experiments, the 10PANX ACETATE shows a remarkable inhibition effect on MZF1 overexpression cells, including inhibition of cell viability, proliferation and clone formation ability and down-regulation of MZF1 protein expression, and the 10PANX ACETATE shows a remarkable inhibition effect on MZF1 overexpression cells. In addition, the compound has a remarkable curative effect on the living body level, is high in safety and has no obvious toxic or side effect. Therefore, the 10PANX ACETATE provides a brand new drug candidate for prevention and treatment of MZF1 overexpression related diseases such as colon cancer, and has important clinical application value and wide market prospect.

According to the isolated culture identification and key marker detection method for the down producing goat hair follicle stem cells, trypsin and EDTA are used for jointly digesting skin tissue, and high-activity cells are efficiently obtained; a culture medium containing various growth factors is adopted for culture, and cell proliferation and stemness maintenance are promoted. And identifying and integrating morphological observation, growth curve determination and clone formation experiment to accurately judge the characteristics of the cells. Immunofluorescent staining and real-time fluorescent quantitative PCR are applied to key marker detection, and expression of markers such as CK15, CD34 and beta1 integrin is detected with high sensitivity. The method is high in separation efficiency, accurate in identification and sensitive in marker detection, can provide sufficient high-quality cells for the research on the hair follicle stem cells of the cashmere goat, assists in deeply understanding the biological characteristics and the regulation mechanism of the cells, and is of great significance for improving the yield and quality of cashmere and promoting the development of related biotechnologies.

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

Biopharmaceutical products require sterility testing to ensure their safe use as injected medicines. The present invention performs this task automatically. By testing the entire fluid volume using optical sensors with no blind spots, the system described herein counts and measures both microbial and subvisible particle contaminants immediately and without modification of the tested products. Actionable data collected by the system includes classification or identification of contaminants and other objects via light-based measurements at the level of each single cell, colony forming unit, or particle.

The invention discloses an HMGB3 inhibitor and application of the HMGB3 inhibitor in preparation of a medicine for treating liver cancer, and relates to the field of molecular biology and biological medicine. The application has the advantages that HCC cell proliferation and clone formation are inhibited through HMGB3shRNA, so that HCC transplanted tumor growth is inhibited, HMGB3 is knocked down to up-regulate expression of TNF, NFKBIA and other genes and down-regulate expression of CARD11 and other genes, NF-kappa B nuclear translocation degradation IKK is further inhibited, in-vitro proliferation and invasion ability of hepatocellular carcinoma cells can be seriously affected, development of liver cancer can be inhibited, and the application has a good application prospect. The compound can be used for preparing anti-hepatoma drugs.

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.

This invention discloses the application of total paeoniflorin in the preparation of drugs for the treatment of head and neck squamous cell carcinoma, belonging to the field of biomedical technology. Addressing the bottlenecks in current treatments for head and neck squamous cell carcinoma, such as high toxicity of radiotherapy and chemotherapy, low response rates to immunotherapy, and easy resistance to targeted drugs, this invention provides a method for preparing total paeoniflorin and a drug-loaded preparation technology based on hydrogels obtained from modified chitosan. Total paeoniflorin can dose-dependently inhibit the proliferation rate, colony formation ability, and in vitro migration ability of SCC7, FADU, and CAL27 head and neck squamous cell carcinoma cell lines, and significantly induce apoptosis. This invention utilizes the multi-target effects of total paeoniflorin to exert anti-head and neck squamous cell carcinoma effects through modulation of the tumor microenvironment and enhancement of immune surveillance. Furthermore, the loaded drug exhibits good sustained-release properties and biosafety, providing a new, highly effective, and low-toxicity strategy for the treatment of head and neck squamous cell carcinoma, and has significant clinical application value.

The invention relates to the technical field of biological medicine, in particular to application of a steroid compound shown in a formula I in preparation of anti-hepatoma drugs. The application finds that medoxone can significantly inhibit malignant growth, plate clone formation ability and apoptosis promoting ability of liver cancer cells MHCC97H through research for the first time, and further finds that the binding affinity of medoxone and TDP-43 protein is relatively high, and medoxone can significantly inhibit expression of the TDP-43 protein along with increase of drug concentration, so that medoxone has a very good anti-liver cancer effect.

The present invention relates to a method for preparing a cosmetic sample, which is characterized in that: six kinds of mixed microorganisms comprising five kinds of bacteria, i.e., Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Burkholderia cepacian, and Enterobacter cloacae, and Candida albicans yeast, are inoculated into a cosmetic sample to be tested, and are stored; a sample collected from the cosmetic to be tested during the storage period is inoculated into an agar culture medium to which tetrazole blue is added and cultured; the number of viable cells corresponding to the total number of colony formation units measured in a short-time culture state is reduced by a predetermined number or more with respect to the theoretical number of cells inoculated in the agar culture medium.